Virtu Financial LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Virtu Financial LLC purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 17,917 shares of the company’s stock, valued at approximately $207,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Clearbridge Investments LLC increased its position in shares of Roivant Sciences by 51.3% during the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock worth $19,666,000 after acquiring an additional 630,712 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Roivant Sciences by 40.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock valued at $6,840,000 after purchasing an additional 185,226 shares in the last quarter. Exchange Traded Concepts LLC acquired a new stake in Roivant Sciences during the 3rd quarter valued at approximately $2,267,000. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences during the 3rd quarter worth approximately $46,333,000. Finally, SG Americas Securities LLC purchased a new position in shares of Roivant Sciences during the 2nd quarter valued at approximately $472,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Activity

In other news, CAO Rakhi Kumar sold 250,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the completion of the transaction, the chief accounting officer now owns 209,322 shares in the company, valued at approximately $2,488,838.58. This represents a 54.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares in the company, valued at approximately $210,693,701.97. This represents a 9.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,677,309 shares of company stock valued at $43,283,184. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Stock Down 3.8 %

ROIV opened at $11.69 on Thursday. The company’s 50-day moving average price is $11.92 and its 200 day moving average price is $11.47. Roivant Sciences Ltd. has a fifty-two week low of $9.69 and a fifty-two week high of $13.06. The firm has a market cap of $8.51 billion, a price-to-earnings ratio of 2.07 and a beta of 1.25.

Analyst Ratings Changes

Several research firms recently issued reports on ROIV. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Bank of America boosted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.